epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-118, Phase II. In start-up

Treatment-resistant major depressive disorder

FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.

When will this study finish recruiting? Set its sites yourself, or let the planner find the fewest per country that meet the deadline.

Study and plan

Fabrikam Neuroscience (fictional), Phase II, CNS and psychiatry. Month 0 is May 2026.
Randomise 243 (drop-out 26%) and screen about 566 (screen failure 57%)
May 2029
Confidence wanted
Sites per country
Edit the site counts in the table below
How much sites differ
Spread of site rates (coefficient of variation 0.9). Fitted trials range from 0.7 to 1.2.
  • Central finish (P50)Feb 2029month 33.3
  • Fast case (P10)Aug 2028month 27.9
  • Slow case (P90)Sep 2029month 41.0
  • Chance of meeting the deadline69%wanted 85%
  • Sites13533% likely to recruit nobody
  • Patients to screen566to randomise 243

On course to finish in February 2029, three months before the deadline

EPI-118, patients randomised, cumulative by monthThe band holds 80% of 4,000 simulated studies; the coloured line is the central forecast; the line marked Actual is recruitment so far

Show data
Patients randomised by month: fast, central and slow cases of the simulation, and actual recruitment
MonthFast caseCentralSlow caseActual
May 20260000
Aug 20260000
Nov 2026000–
Feb 2027952–
May 2027292012–
Aug 2027604329–
Nov 2027997352–
Feb 202814210677–
May 2028186139102–
Aug 2028229172127–
Nov 2028243205152–
Feb 2029243239177–
May 2029243243202–
Aug 2029243243227–
Nov 2029243243243–
Feb 2030243243243–
May 2030243243243–

Source: epiClinical Poisson-gamma simulation; actual recruitment to September 30th 2026. All data synthetic.

How likely is it to finish by a given month?

About a two-in-three chance of finishing by May 2029

Finish month of 4,000 simulated studiesOne dot = 40 simulated studies · 69 of 100 dots finish in time

Drag the handle or
In time: 69%Median Feb 2029Late: 31%

Source: epiClinical Poisson-gamma simulation

Show data
Chance that recruitment is complete by the end of each month
MonthChance complete by then
May 20260%
Aug 20260%
Nov 20260%
Feb 20270%
May 20270%
Aug 20270%
Nov 20270%
Feb 20280%
May 20280%
Aug 20286%
Nov 202823%
Feb 202947%
May 202969%
Aug 202983%
Nov 202992%
Feb 203096%
May 203098%

Countries

UseCountryPatients per site per monthSites open betweenCapSitesPatients by finish
United States
0.067
  • Therapeutic area: 0.450 CNS and psychiatry baseline
  • Country: ×0.75 United States
  • Site type: ×1.009 Usual mix in United States, leaning to independent sites
  • Track record: ×0.865 Expected mix for mostly new sites
  • Protocol and population: ×0.55 Highly restrictive eligibility ×0.55
  • Patient acceptability: ×0.55 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8
  • Competing trials: ×0.75 Heavy competition ×0.75
month 5.8 to 11.9 10097
United Kingdom
0.074
  • Therapeutic area: 0.450 CNS and psychiatry baseline
  • Country: ×0.85 United Kingdom
  • Site type: ×0.988 Usual mix in United Kingdom, leaning to independent sites
  • Track record: ×0.865 Expected mix for mostly new sites
  • Protocol and population: ×0.55 Highly restrictive eligibility ×0.55
  • Patient acceptability: ×0.55 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8
  • Competing trials: ×0.75 Heavy competition ×0.75
month 5.7 to 11.7 4445
Spain
0.087
  • Therapeutic area: 0.450 CNS and psychiatry baseline
  • Country: ×1 Spain
  • Site type: ×0.98 Usual mix in Spain, leaning to independent sites
  • Track record: ×0.865 Expected mix for mostly new sites
  • Protocol and population: ×0.55 Highly restrictive eligibility ×0.55
  • Patient acceptability: ×0.55 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8
  • Competing trials: ×0.75 Heavy competition ×0.75
month 9.3 to 15.3 7145
Poland
0.130
  • Therapeutic area: 0.450 CNS and psychiatry baseline
  • Country: ×1.4 Poland
  • Site type: ×1.052 Usual mix in Poland, leaning to independent sites
  • Track record: ×0.865 Expected mix for mostly new sites
  • Protocol and population: ×0.55 Highly restrictive eligibility ×0.55
  • Patient acceptability: ×0.55 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8
  • Competing trials: ×0.75 Heavy competition ×0.75
month 12.8 to 18.8 4156

Country risks to weigh when choosing sites

United States

Two sourced risks

  • All sites

    The first US site opens quickly, but the rest of the US sites open slowly.

    The US activates its first site quickly but scales its site fleet slowly · PM-03 · grade B

    Tightens: site activation overdue

  • All sites

    Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies.

    Racial and ethnic under-representation · PB-12 · grade A

United Kingdom

Two sourced risks

  • Some sites

    Costing and contracting were the longest start-up step; the national contract has shortened it.

    Fragmented, negotiated costing and contracting · POL-03 · grade A

  • If it recurs

    The regulator's backlog of 2023 was cleared, but could recur.

    Regulator assessment backlog · POL-02 · grade A

Spain

Two sourced risks

  • All sites

    Site contracts took 117 days in 2016 and about 90 after national templates.

    Fragmented, negotiated costing and contracting · POL-03 · grade A

  • All sites

    Applications go through the EU Clinical Trials Regulation and its portal.

    Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A

Poland

Two sourced risks

  • All sites

    Applications go through the EU Clinical Trials Regulation and its portal.

    Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A

  • All sites

    A central ethics committee reviews every study; its effect on timelines is not measured.

    Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness) · POL-20 · grade B

Risk-register entries; the choice of entries per country is epiClinical's.